GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » Pre-Tax Income

NYMXF (Nymox Pharmaceutical) Pre-Tax Income : $-8.84 Mil (TTM As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Nymox Pharmaceutical's pretax income for the three months ended in Dec. 2023 was $-5.31 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.84 Mil. Nymox Pharmaceutical's pretax margin was %.

During the past 13 years, Nymox Pharmaceutical's highest Pretax Margin was -157.49%. The lowest was -234760.00%. And the median was -4616.20%.


Nymox Pharmaceutical Pre-Tax Income Historical Data

The historical data trend for Nymox Pharmaceutical's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical Pre-Tax Income Chart

Nymox Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pre-Tax Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.16 -11.74 -12.54 -6.58 -8.84

Nymox Pharmaceutical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.34 -1.39 -1.11 -1.04 -5.31

Competitive Comparison of Nymox Pharmaceutical's Pre-Tax Income

For the Biotechnology subindustry, Nymox Pharmaceutical's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nymox Pharmaceutical's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's Pre-Tax Income falls into.



Nymox Pharmaceutical Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Nymox Pharmaceutical's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-8.35+-0.439+-0.061+0.006+0
=-8.84

Nymox Pharmaceutical's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-4.85+0+-0.022+0+-0.439
=-5.31

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.84 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nymox Pharmaceutical  (OTCPK:NYMXF) Pre-Tax Income Explanation

Nymox Pharmaceutical's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pretax Income/Revenue
=-5.311/0
=%

During the past 13 years, Nymox Pharmaceutical's highest Pretax Margin was -157.49%. The lowest was -234760.00%. And the median was -4616.20%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nymox Pharmaceutical Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Nymox Pharmaceutical Business Description

Traded in Other Exchanges
N/A
Address
Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Executives
James George Robinson director 10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen officer: Chief Financial Officer 9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback director, 10 percent owner, officer: CEO C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham director, officer: General Counsel

Nymox Pharmaceutical Headlines

From GuruFocus

NYMOX Update

By Marketwired 07-07-2023

Nymox Provides Current Update

By sperokesalga sperokesalga 05-10-2023

NYMOX Updates Shareholders

By PurpleRose PurpleRose 07-15-2022

NYMOX Presenting at Torrey Hills Capital Emerging Growth Conference

By GlobeNewswire GlobeNewswire 11-15-2021

NYMOX Receives Deficiency Letter from NASDAQ

By PurpleRose PurpleRose 07-14-2022

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 05-23-2022

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 06-12-2022

NYMOX Appeals Deficiency Letter

By Stock market mentor Stock market mentor 01-06-2023